Prevalence of Pulmonary Hypertension (PAH) in Patients With Thalassemia

Pulmonary Arterial Hypertension Clinical Trial

— PAH2010  

Official title:

Observational Multicenter Study Lasting 12 Months to Determine the Prevalence of Pulmonary Hypertension (PAH) in Patients With Thalassemia Major and Intermedia and Verify the Suitability of Common Diagnostic Criteria in This Population

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01496963
• Other study ID #: PAH2010
• Status: Completed
• Start date: January 2012
• Est. completion date: December 2021

Study information

• Verified date: August 2022
• Source: Ente Ospedaliero Ospedali Galliera
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a multicenter observational case-control analysis lasting 12 months aimed at determining the prevalence of pulmonary hypertension (PAH) in patients with Thalassemia Major and Intermedia. The patients will be followed, treated and examined according to the best standard clinical practice dictated by the Italian Society for the study of Hemoglobinopathies (SITE), Thalassemia International Federation (TIF)and the Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT) guidelines.

Description:

The most recent International Classification of pulmonary arterial hypertension (PHA) include Hemoglobinopathies in Class I. At present there is no determination of the prevalence of this disease in a large population of thalassemic patients followed in a uniform way. The diagnostic criteria used for the normal population may not be suitable for a population such as thalassemia patients who present features like chronic anemia, iron overload, liver disease, endocrine disorders, etc. The criteria used to define the disease (PHA) will be those ones dictated by the above mentioned guidelines. Primary Objective of the study is the determination of the prevalence and severity of PHA in thalassemia syndromes, recently introduced in Class I of the Classification of PHA. Secondary objectives are: Critical evaluation of current diagnostic criteria derived from those applied to the general population, taking into account the peculiarities of the observed disease in the thalassemic population. Evaluation of sensitivity and specificity of echocardiogram versus right cardiac catheterization (RHC). Evaluation of the correlation between: echocardiography and RHC; resistance and heart rate determined both by RHC and echocardiography; Determination of the patients resulted vasoreactive during RHC. Validation of sensitivity and specificity (sens/spec) of 6 minutes walking test (6MWT) and brain natriuretic peptide (BNP) in Thalassemia Major (TM) and Intermediate (TI) with reference to specific pulmonary hypertensive disease In order to achieve the objectives of the study observed patients will be divided into group according to the following the criteria: group a) - Pulmonary artery pressure (PAP) assessed (by echocardiogram) < 36 mmHg or a tricuspid regurgitant jet velocity (TG) < 3 m/sec and data on PAP and mean left ventricular ejection fraction (LVEF) > 50% group b) - PAP estimated (by echocardiography)> 40 mmHg or TG > 3.2 m / sec and LVEF> 50% - As indicated by the Guidelines, patients b) with increased PAP (TG > 3.2 m / sec or > 40 mm Hg) will be further studied using RHC and vasoreactivity testing. Angio CAT, 6MWT and BNP. group c) - PAP estimated (by echocardiography) in the range of values > 3 m/sec (TG) and < 3.2 m / sec or > 36 mm Hg and <40 mmHg and LVEF > 50% Each case included both in group b) and c) will be paired with two controls included in the group a) to make the groups more comparable. The group a) will serve as control group to compare the diagnostic methods evaluated as per protocol. In order to divide the patients into the three groups specified above first it will be evaluated: PAP, LVEF% and TG assessed by echocardiographic examination performed in the six months prior to the beginning of the study (thalassemic patients have to perform echocardiography once a year to monitor cardiac function according to the guidelines) Patients belonging to groups a), b) and c) will perform the following assessments: - Clinical cardiac evaluation according to the New York Heart Association (NYHA) (functional class I to IV) As per the International Guidelines, patients belonging to groups b) and c) have clinical indications to undergo Two-dimensional echocardiography-Doppler Duplex Scanner (PW) and color flow (CW) to determine the following parameters: - End-systolic volume and left ventricular end diastolic, indexed according to body surface - Percentage change of right ventricular areas (area diastolic/systolic area expressed as a percentage%) - Tricuspid lateral annulus excursion Longitudinal (TAPS) - Eccentricity Index (EI) - TG - Pulmonary resistance. Moreover, patients belonging to group b), according to the International Guidelines have clinical indication to undergo RHC, diagnostic evaluation to rule out the presence of associated diseases and to measure: - Pulmonary pressures - Mean atrial pressure - Pulmonary resistance - Cardiac rate - Vasoreactivity test To compare the data derived from the RHC and the echocardiography the following echocardiographic parameters will be further evaluated: Right atrial pressure; Cardiac output; Pulmonary wedge pressure

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1500
• Est. completion date: December 2021
• Est. primary completion date: December 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients with Thalassemia Major Patients or Intermediate referring to Centres using Web-Thal medical record (a clinical data sheet used for congenital anemias. Info: www.thalassemia.it)

Exclusion Criteria:

• Patients who are considered potentially unreliable and/or not cooperative

Related Conditions & MeSH terms

• beta-Thalassemia
• Hypertension
• Hypertension, Pulmonary
• Pulmonary Arterial Hypertension
• Thalassemia
• Thalassemia Intermedia
• Thalassemia Major

Intervention

Other:
• Physician standard-of-care according to ESC/ERS Guidelines
Physician standard-of-care

Locations

Country	Name	City	State
Italy	Divisione di Ematologia Ospedale Perrino	Brindisi
Italy	Clinica pediatrica Ospedale Microcitemico	Cagliari
Italy	DH Microcitemia dell'adulto Ospedale Microcitemico	Cagliari
Italy	Centro della Microcitemia e delle Anemie Congenite -Ematologia e Cardiologia E.O. Ospedali Galliera	Genoa
Italy	Centro Anemie Congenite Università di Milano IRCCS Ospedale Maggiore Policlinico	Milan
Italy	Dipartimento di pediatria "F.Fede" A.O. Universitaria FedericoII di Napoli	Napoli
Italy	U.O.C- Cardiologia Ospedale San Francesco	Nuoro
Italy	SCDU Microcitemie-Pediatria A.O. Universitaria S.Luigi Gonzaga di Orbassano	Orbassano	Turin

Sponsors (1)

Lead Sponsor	Collaborator
Ente Ospedaliero Ospedali Galliera

Country where clinical trial is conducted

Italy, 

References & Publications (1)

Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT), Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009 Dec;34(6):1219-63. doi: 10.1183/09031936.00139009. Epub 2009 Sep 12. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determination of the prevalence	Determination of the prevalence, defined as the total number of cases in the population, divided by the number of individuals in the population.	12 months
Secondary	Critical evaluation of current diagnostic criteria	Critical evaluation of current diagnostic criteria taking into account the peculiarities of the observed of PHA in thalassemic patients.	12 months